Journal Article Scrutiny Increases In Recent FDA Ad Division Letters
Executive Summary
FDA is scrutinizing use of published studies in promotional campaigns more closely, recent untitled letters issued by the agency's Division of Drug Marketing, Advertising & Communication indicate.
You may also be interested in...
FDA Misgivings About Reprints Would Not Make Them "False" - WLF Lawyer
FDA will not be permitted to object to off-label reprints as "false and misleading" when the agency finds technical problems with an article, attorney Daniel Troy (Wiley, Rein & Fielding) asserted at an Aug. 18 Washington Legal Foundation forum on the impact of the recent WLF v. Henney off-label information dissemination ruling.
Compliance Claim Guidance Being Considered By FDA - DDMAC's Palmer
Promotional "compliance claims" may be the next subject tackled in a draft guidance from FDA's Division of Drug Marketing, Advertising & Communications, Branch Chief Leah Palmer told the Drug Information Association annual meeting.
Vivus Is Preparing Revised TV Ads For Muse Following FDA NOV Letter
Vivus is in discussions with FDA regarding revised TV broadcast ads for its erectile dysfunction therapy, Muse (alprostadil), following receipt of a notice of violation letter from the agency objecting to certain aspects of the company's TV and print ad campaigns.